Mepivacaine

Local anesthesia is a core measure for pain control in surgical operations and invasive procedures. Amide local anesthetics have long occupied the mainstream clinical position due to their stable effect and low allergy rate. As an amide medium-acting local anesthetic, mepivacaine reversibly blocks the sodium channels of nerve cell membranes and inhibits the generation and conduction of nerve impulses, achieving moderate separation of motor and sensory block. Its onset time is about 5-15 minutes, and the duration of action can reach 2-3 hours. Its clinical indications include infiltration anesthesia, nerve block anesthesia, epidural anesthesia, as well as anesthesia needs for small and medium-sized operations in stomatology, plastic surgery, orthopedics, etc., and it is especially suitable for patient groups who have medium requirements for anesthesia duration and hope to quickly recover motor function after surgery.

The global market size of local anesthetics has exceeded 4 billion US dollars in 2024, among which amide varieties account for nearly 75%. Mepivacaine has both efficacy and safety advantages, and its annual compound market growth rate is maintained at about 4.2%. In the domestic market, this variety is still dominated by imported original research products at present, with a small number of local generic enterprises. The annual terminal sales in public medical institutions have exceeded 300 million yuan. With the continuous increase of primary surgical diagnosis and treatment and outpatient surgery volume, there is still room for further release of demand.

The original research enterprise of mepivacaine is Sanofi Winthrop Industrie of France, and the original research trade name is Carbocaine. The core compound patent expired in 1988. The original research dosage forms include injections, with specifications covering 20ml:400mg, 10ml:200mg, etc. It has been included in the FDA Reference Listed Drug Catalog, and also included in the *Catalog of Reference Preparations for Chemical Drugs* of China. At present, the mepivacaine API of multiple domestic enterprises has obtained A status through CDE registration, and the domestic mepivacaine hydrochloride/epinephrine injection has also been approved for marketing. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of mepivacaine impurity reference standards, covering a full series of research reference substances such as synthesis process impurities and degradation impurities. Most products are in stock, and orders placed before 16:00 can be shipped on the same day. The products also meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the compliance needs of multiple scenarios such as API production, quality research, and generic drug consistency evaluation.